◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PBYI

Puma Biotechnology Inc (PBYI) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-02

Puma Biotechnology Inc (PBYI) operates in the BIOTECHNOLOGY industry and is headquartered in Los Angeles, United States with about 179 employees. Its market capitalization is roughly $539 million. In the fiscal year ended 2025-12-31, PBYI reported $228M in revenue and $31M in net income.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

Interactive charts & full statements → Open the PBYI valuation workbench →

PBYI Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Revenue	$231M	$228M	$230M	$236M	$228M	$253M	$225M	$272M	$251M	$28M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—
Gross Profit	$172M	$170M	$166M	$173M	$173M	$189M	$186M	$235M	$216M	$22M	($1M)	($1M)	$0M	$0M	$0M	$0M	—	—	—	—
Gross Margin %	74.5%	74.5%	72.1%	73.4%	75.8%	74.8%	82.5%	86.5%	86.2%	79.8%	—	—	—	—	—	100.0%	—	—	—	—
Operating Income (EBIT)	$31M	$37M	$31M	$33M	$24M	$1M	($30M)	($76M)	($95M)	($292M)	($277M)	($240M)	($142M)	($55M)	($74M)	($10M)	$0M	$0M	$0M	($15M)
Operating Margin %	13.4%	16.3%	13.4%	13.9%	10.4%	0.5%	-13.5%	-27.8%	-37.7%	-1055.6%	—	—	—	—	—	3613.2%	—	—	—	—
Net Income	$26M	$31M	$30M	$22M	$0M	($29M)	($60M)	($76M)	($114M)	($292M)	($276M)	($239M)	($142M)	($55M)	($74M)	($10M)	$0M	$0M	$0M	($15M)
Net Margin %	11.3%	13.6%	13.1%	9.2%	0.0%	-11.5%	-26.7%	-27.8%	-45.3%	-1054.1%	—	—	—	—	—	3640.3%	—	—	—	—
EBITDA	$48M	$53M	$48M	$48M	$22M	($5M)	($36M)	($52M)	($95M)	($288M)	($275M)	($240M)	($142M)	($54M)	($74M)	($10M)	$0M	$0M	$0M	($15M)
Earnings Per Share (EPS)	$0.52	$0.61	$0.62	$0.45	$0.00	$-0.72	$-1.52	$-1.95	$-2.99	$-7.86	$-8.29	$-7.45	$-4.73	$-1.90	$-3.42	$-0.51	$-0.01	$-0.01	$-0.00	$-0.38
Shares Outstanding (M)	53M	51M	49M	48M	45M	41M	40M	39M	38M	37M	33M	32M	30M	29M	22M	—	3M	3M	—	39M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PBYI Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$57M	$45M	$75M	$54M	$52M	$46M	$59M	$81M
Gross Profit	$44M	$34M	$52M	$42M	$40M	$35M	$45M	$51M
Gross Margin %	77.9%	76.7%	69.3%	77.6%	76.5%	77.1%	76.4%	63.9%
Operating Income (EBIT)	$8M	($4M)	$17M	$10M	$7M	$4M	$13M	$22M
Operating Margin %	13.4%	-8.5%	22.7%	17.6%	12.7%	8.7%	22.6%	27.4%
Net Income	$8M	($4M)	$13M	$9M	$6M	$3M	$19M	$20M
Net Margin %	14.5%	-8.4%	17.8%	16.2%	11.2%	6.5%	32.7%	25.2%
EBITDA	$14M	$0M	$21M	$13M	$11M	$8M	$18M	$27M
Earnings Per Share (EPS)	$0.16	$-0.07	$0.26	$0.17	$0.12	$0.06	$0.39	$0.41
Shares Outstanding (M)	53M	51M	52M	51M	50M	50M	49M	49M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PBYI Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Cash from Operations (CFO)	$41M	$42M	$39M	$27M	($16M)	$21M	$1M	$22M	($24M)	($172M)	($142M)	($154M)	($77M)	($55M)	($44M)	($2M)	($18M)	($17M)	($12M)	($15M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$13M	$7M	$0M	$20M	$0M	$1M	$50M	$7M	$1M	$1M	$1M	$1M	$1M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$41M	$42M	$39M	$14M	($23M)	$21M	($19M)	$22M	($25M)	($223M)	($149M)	($156M)	($78M)	($56M)	($45M)	($3M)	($18M)	($17M)	($12M)	($15M)
FCF Margin %	17.8%	18.3%	16.9%	6.1%	-10.0%	8.2%	-8.6%	8.1%	-9.8%	-804.8%	—	—	—	—	—	895.7%	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PBYI Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$2M	$15M	$14M	$10M	$14M	$4M	$16M	$11M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$2M	$15M	$14M	$10M	$14M	$4M	$16M	$11M
FCF Margin %	2.9%	34.4%	19.1%	17.7%	26.8%	7.7%	26.4%	13.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PBYI Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Assets	$193M	$216M	$213M	$231M	$222M	$227M	$244M	$235M	$259M	$166M	$253M	$240M	$163M	$104M	$152M	$55M	$0M	$0M	$0M	$1M
Cash & Cash Equivalents	$37M	$30M	$69M	$85M	$76M	$63M	$85M	$60M	$108M	$82M	$194M	$32M	$38M	$43M	$137M	$53M	$0M	$0M	$0M	$1M
Total Liabilities	$54M	$86M	$121M	$177M	$200M	$229M	$250M	$217M	$225M	$112M	$43M	$34M	$46M	$20M	$23M	$1M	—	$0M	$0M	$1M
Total Debt (Short + Long-Term)	$0M	$24M	$73M	$104M	$102M	$101M	$101M	$98M	$152M	$97M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$139M	$130M	$92M	$53M	$22M	($2M)	($6M)	$17M	$34M	$53M	$210M	$206M	$117M	$84M	$129M	$54M	$0M	$0M	$0M	$1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PBYI viewer.

Other Companies in BIOTECHNOLOGY

ACRS · Aclaris Therapeutics Inc — $580 million
CLYM · Climb Bio Inc — $560 million
STTK · Shattuck Labs Inc — $549 million
DRUG · Bright Minds Biosciences Inc — $542 million
NGNE · Neurogene Inc — $534 million
ENTX · Entera Bio Ltd — $530 million
VALN · Valneva SE ADR — $522 million
FTH · Faeth Therapeutics, Inc. — $508 million

← PBWN All “P” companies PC →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.